The estimated Net Worth of Richard I Steinhart is at least 407 千$ dollars as of 14 June 2024. Mr. Steinhart owns over 1,083 units of BioXcel Therapeutics Inc stock worth over 3,216$ and over the last 11 years he sold BTAI stock worth over 0$. In addition, he makes 403,997$ as Chief Financial Officer at BioXcel Therapeutics Inc.
Richard has made over 11 trades of the BioXcel Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 1,083 units of BTAI stock worth 596$ on 14 June 2024.
The largest trade he's ever made was exercising 5,000 units of BioXcel Therapeutics Inc stock on 14 May 2023 worth over 2,750$. On average, Richard trades about 507 units every 58 days since 2014. As of 14 June 2024 he still owns at least 5,848 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Mr. Steinhart stock trades at the bottom of the page.
Richard I. Steinhart, CPA is the Chief Financial Officer of the Company. From October 2015 to June 2017 he was Vice President and CFO at Remedy Pharmaceuticals, Inc. From January 2014 to September 2015 Mr. Steinhart worked as a financial and strategic consultant to the biotechnology and medical device industries. From April 2006 through December 2013, Mr. Steinhart was employed by MELA Sciences, Inc., as their Vice President, Finance and Chief Financial Officer, Treasurer and Secretary from April 2006 to April 2012 and as Sr. Vice President, Finance and Chief Financial Officer from April 2012 to December 2013. From May 1992 until joining MELA Sciences, Mr. Steinhart was a Managing Director of Forest Street Capital/SAE Ventures, a boutique investment banking, venture capital, and management consulting firm focused on healthcare and technology companies. Prior to Forest Street Capital/SAE Ventures, he was Vice President and Chief Financial Officer of Emisphere Technologies, Inc. Mr. Steinhart's other experience includes seven years at CW Group, Inc., a venture capital firm focused on medical technology and biopharmaceutical companies, where he was a General Partner and Chief Financial Officer. Mr. Steinhart is a member of the Board of Directors of Actinium Pharmaceuticals, Inc., a position he assumed in November 2013, and Atossa Genetics, Inc., where he began his service in March 2014. Mr. Steinhart serves as the Chairman of the Audit Committee at Actinium Pharmaceuticals, where he also sits on the Corporate Governance Committees. Mr. Steinhart serves as the Chairman of Atossa Genetics Audit Committee and is a member of its Compensation Committee. He holds B.B.A. and M.B.A. degrees from Pace University and is a Certified Public Accountant (inactive).
As the Chief Financial Officer of BioXcel Therapeutics Inc, the total compensation of Richard Steinhart at BioXcel Therapeutics Inc is 403,997$. There are 4 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of 1,968,930$.
Richard Steinhart is 63, he's been the Chief Financial Officer of BioXcel Therapeutics Inc since 2017. There are 3 older and 10 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
Richard's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC.,, 107 SPRING STREET, SEATTLE, WA, 98104.
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over 63,244,788$ worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth 321,105$ . The most active insiders traders include Vimal Bio Xcel Holdings, In...、Vimal Mehta、Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 29,814$. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth 413$.
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include: